Literature DB >> 25825583

Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.

Sanjeev Kumar Sharma1, Suman Kumar1, Narendra Agrawal1, Pravas Mishra1, Tulika Seth1, Manoranjan Mahapatra1.   

Abstract

Management of pure red cell aplasia following major ABO-mismatched hematopoietic stem cell transplantation is a therapeutic challenge. Various therapeutic modalities have been tried with variable responses, and patient remains transfusion dependent for a long time. We report here the use of pulsed oral high dose dexamethasone for pure red cell aplasia following ABO-mismatched allogeneic transplant with complete recovery.

Entities:  

Keywords:  ABO-mismatched allogeneic stem cell transplantation; Oral pulsed high dose dexamethasone; Pure red cell aplasia

Year:  2013        PMID： 25825583      PMCID： PMC4375135          DOI： 10.1007/s12288-013-0276-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  9 in total

1.  Pharmacokinetics of high-dose oral and intravenous dexamethasone.

Authors:  G G Tóth; C Kloosterman; D R Uges; M F Jonkman
Journal:  Ther Drug Monit       Date:  1999-10       Impact factor: 3.681

2.  Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review.

Authors:  M H Yang; H C Hsu
Journal:  Ann Hematol       Date:  2001-05       Impact factor: 3.673

3.  Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation.

Authors:  U R Deotare; A Vishwabandya; V Mathews; B George; A Srivastava; M Chandy
Journal:  Bone Marrow Transplant       Date:  2006-05-08       Impact factor: 5.483

Review 4.  Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin.

Authors:  A Santamaría; A Sureda; R Martino; A Domingo-Albós; E Muñiz-Díaz; S Brunet
Journal:  Bone Marrow Transplant       Date:  1997-12       Impact factor: 5.483

5.  Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia.

Authors:  A A Maschan; E V Skorobogatova; D N Balashov; E D Pashanov; P E Trakhtman; I P Schipitzina; Y V Skvortsova; A G Rumiantzev
Journal:  Bone Marrow Transplant       Date:  2002-09       Impact factor: 5.483

6.  Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.

Authors:  Grzegorz Helbig; Beata Stella-Holowiecka; Jerzy Wojnar; Malgorzata Krawczyk; Slawomira Krzemien; Maria Wojciechowska-Sadus; Mirosław Markiewicz; Iwona Wylezol; Malgorzata Kopera; Jerzy Holowiecki
Journal:  Ann Hematol       Date:  2007-05-08       Impact factor: 3.673

7.  Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation.

Authors:  J P Gmür; J Burger; A Schaffner; K Neftel; O Oelz; D Frey; M Metaxas
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

8.  Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation.

Authors:  E A Sahovic; J Flick; C D Graham; R K Stuart
Journal:  Am J Med Sci       Date:  1991-12       Impact factor: 2.378

9.  Primary dexamethasone treatment of multiple myeloma.

Authors:  R Alexanian; M A Dimopoulos; K Delasalle; B Barlogie
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.